印度高危人群HIV暴露前预防与检测策略的成本效果
该研究用印度数据构建HIV微模拟模型,比较男男性行为者(MSM)和注射吸毒者(PWID)的7种检测与暴露前预防(PrEP)策略。结果显示PrEP联合每6个月检测对MSM(ICER 1000美元/年挽救生命)和PWID(ICER 500美元/年挽救生命)均具成本效果。
要点
- PrEP联合每6个月检测对印度MSM和PWID均具成本效果。
- 单独HIV检测可延长MSM寿命0.07–0.30年,PrEP额外增加约0.90生命年。
核心结论
- PrEP联合每6个月检测是印度MSM和PWID具成本效果的HIV预防策略。
- 结果对HIV发病率最敏感,高发病率地区可优先扩大PrEP。
研究设计与样本
- 采用印度特异性数据填充HIV微模拟模型,投影7种策略的临床与经济结局。
- 策略包括现状、一次性HIV检测、每3/6/12个月常规检测、PrEP联合每3或6个月检测。
- 成本效果阈值定义为1950美元(2017年印度人均GDP)。
主要发现
- 单独HIV检测使MSM预期寿命增加0.07–0.30年,PrEP较现状增加约0.90生命年。
- PWID结果与MSM相似。
- PrEP联合6个月检测对MSM的ICER为1000美元/年挽救生命,对PWID为500美元/年挽救生命。
关键数值与推荐
- 成本效果阈值:1950美元(2017年印度人均GDP)。
- PrEP联合6个月检测:MSM ICER 1000美元/年挽救生命,PWID ICER 500美元/年挽救生命。
临床怎么用
- 对印度MSM和PWID可考虑采用PrEP联合每6个月HIV检测作为成本效果策略。
- 全国推广需大量财政投入,可优先在高HIV发病率地区扩大PrEP。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The human immunodeficiency virus (HIV) epidemic in India is concentrated among 3.1 million men who have sex with men (MSM) and 1.1 million people who inject drugs (PWID), with a mean incidence of 0.9-1.4 per 100 person-years. We examined the cost-effectiveness of both preexposure prophylaxis (PrEP) and HIV testing strategies for MSM and PWID in India. METHODS: We populated an HIV microsimulation model with India-specific data and projected clinical and economic outcomes of 7 strategies for MSM/PWID, including status quo; a 1-time HIV test; routine HIV testing every 3, 6, or 12 months; and PrEP with HIV testing every 3 or 6 months. We used a willingness-to-pay threshold of US$1950, the 2017 Indian per capita gross domestic product, to define cost-effectiveness. RESULTS: HIV testing alone increased life expectancy by 0.07-0.30 years in MSM; PrEP added approximately 0.90 life-years to status quo. Results were similar in PWID. PrEP with 6-month testing was cost-effective for both MSM (incremental cost-effectiveness ratio [ICER], $1000/year of life saved [YLS]) and PWID (ICER, $500/YLS). Results were most sensitive to HIV incidence. PrEP with 6-month testing would increase HIV-related expenditures by US$708 million (MSM) and US$218 million (PWID) over 5 years compared to status quo. CONCLUSIONS: While the World Health Organization recommends PrEP with quarterly HIV testing, our analysis identifies PrEP with semiannual testing as the cost-effective HIV prevention strategy for Indian MSM and PWID. Since nationwide scale-up would require a substantial fiscal investment, areas of highest HIV incidence may be the appropriate initial targets for PrEP scale-up.
引用
- Kazemian P, Costantini S, Kumarasamy N, et al. The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India. Clin Infect Dis. 2020. PMID: 30921454. doi:10.1093/cid/ciz249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。